Log in
LON:NCYT

Novacyt Share Forecast, Price & News

GBX 429
+19.00 (+4.63 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
405.11
Now: GBX 429
443
50-Day Range
287.50
MA: GBX 325.05
415
52-Week Range
6.03
Now: GBX 429
529
Volume550,409 shs
Average Volume1.87 million shs
Market Capitalization£302.99 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Novacyt S.A. develops and sells diagnostic products for cancer and infectious diseases. The company's diagnostic products are used in liquid based cytology, oncology, microbiology, haematology, and serology testing. It offers NovaPrep, a liquid based cytology solution that is utilized in the diagnosis of cervical cancer; and clinical laboratory testing services to clinicians, healthcare providers, and patients. The company also develops, manufactures, and distributes diagnostic products for clinical and food laboratories; and manufactures and markets vitro diagnostic tests, as well as diagnostic reagents, test kits, and blood grouping reagents. It serves hospitals and large corporates. The company was founded in 2006 and is based in Vélizy-Villacoublay, France.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.40 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone33 1 39 46 51 04

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book ValueGBX 116.20 per share

Profitability

Miscellaneous

Employees121
Market Cap£302.99 million
Next Earnings DateN/A
OptionableNot Optionable
GBX 429
+19.00 (+4.63 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NCYT News and Ratings via Email

Sign-up to receive the latest news and ratings for NCYT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Novacyt (LON:NCYT) Frequently Asked Questions

How has Novacyt's stock been impacted by COVID-19 (Coronavirus)?

Novacyt's stock was trading at GBX 107.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NCYT shares have increased by 299.1% and is now trading at GBX 429.
View which stocks have been most impacted by COVID-19
.

Who are some of Novacyt's key competitors?

What other stocks do shareholders of Novacyt own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novacyt investors own include Biocept (BIOC), Ecolab (ECL), Genedrive (GDR), Geron (GERN), Immunic (IMUX), Tiziana Life Sciences (TILS), Verastem (VSTM), VYNE Therapeutics (VYNE), Antero Midstream (AM) and Aileron Therapeutics (ALRN).

Who are Novacyt's key executives?

Novacyt's management team includes the following people:
  • Mr. Graham Mullis, CEO & Director (Age 56)
  • Mr. Anthony Dyer, CFO, Company Sec. & Director
  • Ms. Mandy Cowling, Corp. & Investor Relations Mang.
  • Ms. Wendy Karban, Group HR Mang.
  • Mr. Phillip Sefton, Managing Director of Lab21 Products Division

What is Novacyt's stock symbol?

Novacyt trades on the London Stock Exchange (LON) under the ticker symbol "NCYT."

How do I buy shares of Novacyt?

Shares of NCYT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Novacyt's stock price today?

One share of NCYT stock can currently be purchased for approximately GBX 429.

How big of a company is Novacyt?

Novacyt has a market capitalization of £302.99 million. Novacyt employs 121 workers across the globe.

What is Novacyt's official website?

The official website for Novacyt is www.novacyt.com.

How can I contact Novacyt?

The company can be reached via phone at 33 1 39 46 51 04.

This page was last updated on 9/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.